What's the Problem?
The selection of the most appropriate therapy for a cancer patient is based on population meta-analyses that do not guarantee the individual response of each patient. Precision Oncology seeks to identify predictive biomarkers, mainly of the genomic type, that help assign targeted therapies with greater chances of therapeutic success. Unfortunately, these therapies only benefit a small group of cancer patients (~15% qualify for genome-targeted therapies and only around 8% of patients respond favorably). Therefore, clinicians continue to prescribe therapy using the Standard of Care and a trial-and-error dosing approach, which results in a large percentage of patients not responding positively and billions of dollars spent on treatments that ultimately fail.